UNSPSC 51172318: Carglumic acid

This classification denotes an agent affecting blood and body fluid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5L0HB4V1EW. European Medicines Agency schedules Carglumic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20051. Carglumic acid generally arises in the molecular formula C6H10N2O5.

The term CARGLUMIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 3-4, 2001, list 46.) Most nations schedule carglumic acid under HS 29241900 and SITC 51471. As of Q4 2014, CARGLUMIC ACID remains the US FDA Preferred Term for this commodity. Carglumic acid bears US NLM identifiers UMLS ID C1318649 and NCI Concept Code C76884. SMILES: C(CC(=O)O)C(C(=O)O)NC(=O)N.

UNSPSC 51172318 Carglumic acid is a Commodity code that nominally identifies a specific pharmaceutical compound, yet recent state and local procurement activity under this code shows a marked mismatch between the code designation and the work actually being solicited. The three most recent opportunities tagged to this code encompass offender drug testing services, pharmacy benefit program development, and generic pharmaceutical supply contracting — none of which involves carglumic acid procurement or specialty pharmaceutical sourcing aligned to the code's abstract scope. The issuing bodies span county criminal justice departments, state health and human services commissions, and multi-state cooperative purchasing alliances, reflecting fragmented buying across justice, health, and procurement administration silos rather than a coherent commodity demand signal.

Activity concentrates in Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services with a July 23, 2026 response deadline, seeking annual testing capacity of approximately 25,031 tests across two collection sites at an estimated contract value of $600,000 over two years with optional three one-year renewals. The Texas Health and Human Services Commission posted RFI HHS0017013 on March 27, 2026 (response deadline April 3, 2026) to gather market intelligence on direct-to-manufacturer pharmaceutical prescription programs, with no award value or formal competitive parameters specified. The Minnesota Department of Administration, administering the MMCAP cooperative purchasing alliance, issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with a response deadline of March 26, 2026 and contract effectiveness of July 1, 2026. The code shows limited relevance to actual state and local procurement activity under its nominal designation.